Their mission is to revolutionize the US$25 billion global animal pharmaceutical market by providing safe and effective therapies for chronic conditions in pets, such as pain and inflammatory diseases, which are poorly treated by current veterinary therapies. Nexvet collaborates with leading contractors, advisors, drug development partners, academic groups, veterinarians, and animal interest groups worldwide to develop their pipeline to the highest standards, leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company.